第七章 結論與建議
第二節 建議
在未來之研究將朝三個方向進行改善：（1）在不同時間檢測實 驗動物肝臟組織細胞激素的基因表現；（2）加作免疫組織化學染色之 研究；（3）加作血漿細胞激素濃度的測定。
參考文獻
1. Chen DS, Sung JL. Hepatitis B Virus infection in Taiwan. N Engl J Med 1997;297:668-9.
2. Chen DS, Sung JL. Hepatitis B Virus infection and its sequelae in Taiwan. Gastroenterol Jpn 1984; 19:363-6.
3. Chen DS, Kuo G, Sung JL, Lai MY, Sheu JC, Chen PJ, et al.
Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990;
162:817-822.
4. Lee SD, Chan CY, Wang YJ, Wu JC, Lai KH, Tsai YT, Lo KJ.
Seroepidemiology of hepatitis C Virus in infection in Taiwan.
Hepatology 1991; 12:830-3.
5. Chen DS, Wang JT, Chen PJ, Wang TH, Sung JL. Hepatitis C Virus infection in Taiwan. Gastroenterol Jpn 1991;26(supple 3):164-6.
6. Chang SJ, Chen HC, Ying J, Lu CF, Ko YC. Risk factors of hepatitis C virus infection in a Taiwanese aboriginal community. Kaohsiung J Med Sci 1996;12: 241-7.
7. Lu SN, Chue PY, Chen IL, Wang JH, Huang JF, Peng CF, et al.
Incidence of hepatitis C infection in a hepatitis C endemic township in southern Taiwan. Kaohsiung J Med Sci 1997; 13:605-8.
8. Lai HC, Chan CY. Clinical study of hypovascular hepatocellular carcinoma. Gastroenteral J Taiwan 2003;20:117.
9. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis: definition, nomenclature and classification. Bull WHO 1977;55:521-40.
10. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis: definition, nomenclature and classification. J Clin Pathol 1978;31:395-414.
11. Leevy CM, Tygstrup N. Standardisation of nomenclature, diagnosis criteria and diagnostic methodology for diseases of the liver and biliary tract. Basel: Karger, 1976
12. Scheuer PJ. Liver biopsy in the diagnosis of cirrhosis. Gut 1970;11:275-8.
13. Millward-Sadler GH. Liver cirrosis. In: MacSween M, Anthony PP, Scheuer PJ, Burt AD, Portmann BC, eds. Pathology of the Liver.
Hong kong: Churchill Livingstone, 1994: 397-420.
14. Kuntz E, Kuntz HD. Clinical findings. In: Kuntz E, Kuntz HD, eds.
Hepatology, Principles and Practice. Berlin: Springer-Verlag, 2001;
64-76.
15. Gatta A, Bolognesi M. Pathophysiology of portal hypertension. In:
Baret AL, Sartor K, Youker JE, eds. Portal Hypertension. Diagnostic Imaging and Imaging-guided Therapy. Berlin: Springer-Verlag; 2000;
1-14.
16. Marteau P, Ballet F, Chazovilleres O. Effect of vasodilators on hepatic circulation in cirrhosis: a study in the isolated perfused rat liver. Hepatology 1989;8:820-3.
17. Poo JL, Braillon A, Hadengue A, Gaudin C, Lebrec D.
Hemodynamic effects of terbutaline, a β2-adrenoreceptor agonist, in conscious rats with secondary biliary cirrhosis. Hepatology 1992;15:459-63.
18. Cummings SA, Groszmann RJ, Kaumann AJ. Hypersensitivity of mesenteric veins to 5-hydroxytryptamine and ketanserin-induced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol 1986;89:501-13.
19. Bhathal PS, Groszmann HJ. Reduction of the increased portal vascular resistance of isolated perfused cirrhotic rat liver by
20. Schneider AW, Kalk JF, Klein CP. Effect of Losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999;29:334-9.
21. Jimenez W, Rodes H. Impaired responsiveness to endogenous vasoconstrictors and endothelium derived vasoactive factors in cirrhosis. Gastroenterology 1994;107:1201-3.
22. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997;25:
2-5.
23. Zhang B, Calmus Y, Wen L, Sogni P, Lotersztajn S, Houssin D, Weill B. Endothelin-1 induces liver vasoconstriction through both ETA and TEB receptors. J Hepatol 1997;26:1104-10.
24. Asbert M, Gines A, Gines P, Jimenez W, Claria J, Salo J, Arroyo V, Rivera F, Rodes J. Circulating levels of endothelin in cirrhosis.
Gastroenterology 1993;104:1485-91.
25. Moller S, Emmeluth C, Henriksen JH. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J Hepatol 1993;19:285-90.
26. Leivas A, Jimenez W, Bruix J, Bosch J, Arroyo V, Rivera F, Rodes J.
Gene expression of endothelin-1 and ETA and ETB receptors in human cirrhosis: relationship with hepatic hemodynamics. J Vasc Res 1998;35:186-93.
27. Poo JL, Jimenez W, Munoz RM, Bosch-Marce M, Bordas N, Morales-Ruiz M, Perez M, Deulofeu R, Sole M, Arroyo V, Rodes J.
Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Gastroenterology 1999;116:161-7.
28. Sogni P, Smith APL, Gadano A, Lebrec D, Higenbottam TW.
Induction of nitric oxide synthase II does not account for excess vascular nitric oxide production in experimental cirrhosis. J Hepatol
29. Shah V, Haddad FG, Garcia-Gardena G, Frangos JA, Mennone A, Groszmann RJ, Sessa WC. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest 1997;100:2923-30.
30. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344-51.
31. Sarela AI, Mihaimeed FMAM, Batten JJ, Davidson BR, Mathie RT.
Hepatic and splanchnic nitric oxide activity in patients with cirrhosis.
Gut 1999;44:749-53.
32. Bolognesi M Sacerdoti D, Merkel C, Gatta A. Relationship between portal blood flow measured by image-directed Doppler ultrasonography and hepatic blood flow measured by indocyanine green constant infusion in patients with cirrhosis. J Clin Ultrasound 1995;23:297-303.
33. Witte CL, Witte MH, Bair G, Mobley WP, Morton D. Experimental study of hyperdynamic vs. stagnant mesenteric blood flow in portal hypertension. Ann Surg 1974;179:304-10.
34. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52-7.
35. Blendis LM. Portal hypertension. In: Lautt WW, ed. Hepatic Circulation in Health and Disease. Reven, New York, 1981:329-50.
36. Bernardi M, Trevisani F. Systemic and regional hemodynamics in pre-ascitic cirrhosis. J Hepatol 1997;27:588-91.
37. Benoit JN, Zimmerman B, Premen AJ, Go VL, Granger DN. Role of glucagon in splanchnic hyperemia of chronic portal hypertension.
Am J Physiol 1986;251: G674-7.
J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
Hepatology 1988;8:1151-7.
39. Sherwin R, Joshi P, Hendler R, Felig P, Conn HO.
Hyperglucagonemia in Lannec’s cirrhosis The role of portal-sytemic shunt. N Engl J Med 1974;290: 239-42.
40. Benoit JN, Womack WA, Hernandez L, Granger DN. “Forward” and
“backward” flow mechanisms of portal hypertension. Relative contributions in a rat model of portal vein stenosis. Gastroenterology 1985;89:1092-6.
41. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis. A role for nitric oxide. Lancet 1991;i:776-8.
42. Bosch J, Pizcueta P, Feu F, Fernandez H, Garcia-Pagan CG.
Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992;21:1-14.
43. Sogni P, Moreau R, Gadano A, Lebrec D. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol 1995;23:218-24.
44. Hori N, Okanoue T, Sawa Y, Kashima K. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats. J Hepatol 1997;26:1111-9.
45. Fernandez-Rodriguez CM, Prada IR, Prieto J, Mntuenga LM, Elssasser T, Quiroga J, Moreiras M, Andrade A, Cuttitta F.
Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. J Hepatol 1998;98:250-6.
46. Guevara M, Bru C, Gines P, Fernandez-Esparrach G, Sort P, Bataller R, Jimenez W, Arroyo V, Rodes J. Increased cerebrovascular
1998;28:39-44.
47. Gatta A, Sacerdoti D, Bolognesi M, Merkel C. Portal hypertension:
state of the art. Ital J Gastroenterol Hepatol 1999;31:326-45.
48. Perez-Ruiz M, Ros J, Morales-Ruiz M, Navasa M, Colmenero J, Ruiz-del-Arbol L, Cejudo P, Claria J, Rivera F, Arroyo V, Rodes J, Jimenez W. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. Hepatology. 1999;29:1057-63.
49. Pak JM, Lee SS. Glucagon in portal hypertension. J Hepatol 1994;20:825-32.
50. Kravetz D, Bosch J, Arderiu MT, Pizcueta MP, Casamitjana R, Rivera F, Rodes J. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988;254:G322-8.
51. Hamilton G, Phing RC, Hutton RA, Dandona P, Hobbs KE. The relationship between prostacyclin activity and pressure in the portal vein. Hepatology 1982;2:236-42.
52. Hou MC, Cahill PA, Zhang S, Wang YN, Hendrickson RJ, Redmond EM, Sitzmann JV. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology 1998;27:20-7.
53. Bruix J, Bosch J, Kravetz D, Mastai R, Rodes J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985;88:430-5.
54. Fernandez M, Garcia-Pagan JC, Casadevall M, Mourelle MI, Pique JM, Bosch J, Rodes J. Acute and chronic blockage in portal-hypertens ive rats: influence in nitric oxide biosynthesis.
Gastroenterology 1996;110:1529-35.
McMurtry I, Schrier RW. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995;109:1624-30.
56. Forrest EH, Jones AL, Dillon JF, Walker J, Hayes PC. The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis. J Hepatol 1995;23:254-8.
57. Garcia-Pagan JC, Bosch J, Rodes J. The role of vasoactive mediators in portal hypertension. Semin Gastrointest Dis 1995;6:140-7.
58. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressor in mesenteric vessels of portal hypertensive rats.
Gastroenterology 1992;103:235-9.
59. Castro A, Jimenez W, Claria J, Ros J, Martinez JM, Bosch M, Arroyo V, Piulats J, Rivera F, Rodes J. Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide.
Hepatology 1993;18:367-72.
60. Balkwill F. Cytokines and cytokine receptors. In: Roitt I, Brostoff J, Male D, eds. Immunology. Edinburgh: Mosby 2000:119-29.
61. Kollas G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor ad receptors in models of multiorgain failure, rheumatoid arthritis multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999;169:175-94.
62. Vaday GG, Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behaviour and inflammation. J Leukocyte Biol 2000;74:457-71.
63. Rojkind M, Greenwel P. The liver as a bioecological system. In:
Arias IM, Jakoby W, Popper H, eds. The Liver: Biology and Pathology. New York: Raven Press, 1988:707-16.
64. Gressner AM. Transdifferentiation of hepatic stellate cells (Ito cells )
Suppl 1996;54:S39-45.
65. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999;19:129-40.
66. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999;19:205-19.
67. De Bleser PJ, Xu G, Rombouts K, Rogiers V, Geerts A. Glutathione levels discriminate between oxidative stress and transforming growth factor-β signaling in activated rat hepatic stellate cells. J Biol Chem 1999;274:33881-7.
68. Garcia-Trevijano ER, Iraburu MJ, Fontana L, Dominguez-Rosales JA, Auster A, Covarrubias-Pinedo A, Rojkind M. Transforming growth factor-β1 induces the expression of α1 (I) procollagen mRNA by a hydrogen peroxide-C/EBPβ-dependent mechanism in rat hepatic stellate cells. Hepatology 1999;29:960-70.
69. Greenwel P, Dominguez-Rosales JA, Mavi G, Rivas-Estilla AM, Rojkind M. Hydrogen peroxide: a link between acetaldehyde-elicited α1 (I) collagen gene upregulation and oxidative stress in mouse hepatic stellate cells. Hepatology 2000;31:109-16.
70. Dominguez-Rosales JA, Mavi G, Levenson SM, Rojkind M. H2O2 is an important mediator of physiological and pathological healing responses. Arch Med Res 2000;3:15-20.
71. Friedman SL. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med 1993;328:1828-35.
72. Pinzani M. Hepatic stellate (Ito) cells: expanding roles for a liver-specific pericyte. J Hepatol 1995;22:700-6.
73. Devière J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J, Dupont E. Excessive in vitro bacterial lipopolysaccharide- induced production of monokines in cirrhosis. Hepatology 1990;11:
628-34.
74. Chung RT, Podolsky DK. Cirrhosis and its complications. In:
Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison’s Principles of Internal Medicine.
McGraw-Hill, New York; 2001:1754-67.
75. Kravetz D, Bosch J, Arderiu M, Pilar Pizcueta M, Rodes J.
Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting. Hepatology 1989;9:808-14.
76. Pizcueta MP, de Lacy AM, Kravetz D, Bosch J, Rodes J. Propranolol decreases portal pressure without changing portal-collateral resistance in cirrhotic rats. Hepatology 1989;10:953-7.
77. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985;248:G618-25.
78. Chu CJ, Lee FY, Chang FY, Wang SS, Lin HC, Wu SL, Tai CC, Lee SD. Hyperdynmic circulation in prehepatic portal hypertension: role of tumor necrosis factor-alpha. Chin Med J (Taipei) 1997;59:145-50.
79. Lay CS, Yang CM, Tsai YT, Chen HI, Simchon S, Chien S. An animal study of portal hypertension. Chin Med J (Taipei) 1989;44:
19-24.
80. Lee FY, Wang SS, Yang MC, Tsai YT, Wu SL, Lu RH, Chan CY, Lee SD. Role of endotoxaemia circulation in rats with extrahepatic or intrahepatic portal hypertension. J Gastroenterol Hepatol 1996;11:152-8.
81. Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the
Hepatology 1992;15:323-8.
82. Lebrec D, Blanchet L. Effect of two models of portal hypertension on splanchnic organ blood flow in the rat. Clin Sci (Lond) 1985;68:23-8.
83. Fallon MB, Abrams GA, McGrath JW, Hou Z, Lou B. Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome. Am J Physiol 1997;274:G779-84.
84. Sikuler E, Buchs AE, Yaari A, Keynan A. Hemodynamic characterization of conscious and ketamine-anesthetized bile -duct- ligated rats. Am J Physiol 1991;260:G161-6.
85. Talor Z. Blunted pressor response to volume load in conscious dogs with chronic bile duct ligation. Med Biol 1982;60:217-20.
86. Bosch J, Enriquez R, Groszmann RJ, Storer EH. Chronic bile duct ligation in the dog: hemodynamic characterization of a portal hypertensive model. Hepatology 1983;3:1002-7.
87. Bomzon A, Rosenberg M, Gali D, Binah O, Mordechovitz D, Better OS, Greig PD, Blendis LM. Systemic hypotension and decreased pressor response in dogs with chornic bile duct ligation. Hepatology 1986;6:595-600.
88. Lee SS, Girod C, Braillon A, Hadengue A, Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: effect of pentobarbital sodium. Am J Physiol 1986;251:G176-80.
89. Beyacrt R, Fiers W. Tumor necrosis factor and lymphotoxin. In:
Mire-sluis A, Thorpe R, eds. Cytokines. Academic Press: San Diego, 1998:335-60.
90. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991;285:199-212.
91. Ruddle NH. Tumor necrosis factor (TNF-alpha) and lymphotoxin
92. Nophar Y, Kemper O, Brakebusch C, Englemann H, Zwang R, Aderka D, Holtmann H, Wallach D. Soluble forms of tumor necrosis factor receptors (TNF -Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990;9:3269-78.
93. Ruscetti FW, Birchenall-Roberts MC, McPherson JM, Wiltrout RH.
Transforming growth factor β1. In: Mire-sluis A, Thorpe R, eds.
Cytokines. Academic Press: San Diego, 1998:415-32.
94. Brown PD, Wakefield LM, Levinson AD, Sporn MB.
Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. Growth Factors 1990;3:35-43.
95. Massague J. Receptors for the TGF-beta family. Cell 1992;69:
1067-70.
96. Franzen P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin CH, Miyazono K. Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell 1993;75:681-92.
97. Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF.
Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992;68:775-85.
98. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 1991;67:785-95.
99. Wang XF, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA. Expression cloning and characterization of the TGF-beta type III receptor. Cell 1991;67:797-805.
Mire-sluis A, Thorpe R, eds. Cytokines. Academic Press: San Diego, 1998:391-8.
101. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993;11:
571-611.
102. Billiau A. Interferon-gamma: biology and role in pathogenesis. Adv Immunol 1996;62:61-130.
103. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD.
How cells respond to interferons. Annu Rev Biochem 1998;67:227-64.
104. Valente G, Ozmen L, Novelli F, Geuna M, Palestro G, Forni G, Garotta G. Distribution of interferon-gamma receptor in human tissues. Eur J Immunol 1992;22:2403-12.
105. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-8.
106. Aguet M. Molecular cloning of interferon receptors: a short review.
Br J Haematol 1991;79 Suppl 1:6-8.
107. Lutfalla G, Gardiner K, Proudhon D, Vielh E, Uze G. The structure of the human interferon alpha/beta receptor gene. J Biol Chem 1992;
267:2802-9.
108. Rodig S, Kaplan D, Shankaran V, Old L, Schreiber RD. Signaling and signaling dysfunction through the interferon gamma receptor.
Eur Cytokine Netw 1998;9(3 Suppl):49-53.
109. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR.
Interleukin-10. Annu Rev Immunol 1993;11:165-90.
110. de Waal Malefyt R, Yssel H, Roncarolo MG, Spits H, de Vries JE.
Interleukin-10. Curr Opin Immunol 1992;4:314-20.
111. Howard M, O'Garra A. Biological properties of interleukin 10.
112. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, Moore KW, Howard M. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 1990;172:1625-31.
113. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 1992;175:671-82.
114. Chojkier M, Groszman RJ. Measurement of portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981;240:G371-5.
115. Franco F, Gigou M, Szekely AM, Bismuth H. Portal hypertension after bile duct obstruction. Effect of bile diversion on portal pressure in the rat. Arch Surg 1979;114:1064−7.
116. Daniluk J, Kandefer-Szerszen M, Borowska L. Tumor necrosis factor and interferon production by peripheral blood leukocytes of patients with alcoholic cirrhosis. Arch Immunol Ther Exp 1996;
44:97-101.
117. Lee FY, Lu RH, Tsai YT, Lin HC, Hou MC, Li CP, et al. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotxemia, tumor encrosis factor-alpha, and hyperdynamic circulation. Scand J Gastroenterol 1996;31:500-5.
118. Neuman M, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002;17:196-202.
119. Perez-Paramo M, Munoz J, Albillos A, Rossi I, Alvarez-Mon M, Ortiz Berrocal J. Evaluation of the hemodynamic effects of tumor
radioactive microsphere technique. Rev Esp Med Necl 1998;17:
294-301.
120. Le Moine O, Soupison T, Sogni P, Marchant A, Moreau R, Hadengue A, et al. Plasma endotoxin and tumor necrosis factor-alpha in the hyperkinetic state of cirrhosis. J Hepatol 1995;23:391-5.
121. Yuen MF, Norris S, Evans LW, Langley PG, Hughes RD.
Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis.
Scand J Gastroenterol2002;37:233-8.
122. Flisiak R, Pytel-Krolczuk B, Prokopowicz D. Circulating transforming growth factors beta(1) as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 2000;12:677-81.
123. Baer HU, Friess H, Abou-Shady M, Berberat P, Zimmermann A, Gold LI, Korc M, Buchler MW. Transforming growth factor betas and their receptors in human liver cirrhosis. Eur J Gastroenterol Hepatol 1998;10:1031-9.
124. Napoli J, Prentice D, Niinami C, Bishop GA, Desmond P, McCaughan GW. Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor beta in a bile duct ligated rat model of cirrhosis. Hepatology 1997;26:634-33.
125. Bories PN, Campillo B, Scherman E. Up-regulation of nitric oxide production by interferon-gamma in cultured peritoneal macrophages from patients with cirrhosisl Clin Sci (Lond) 1999;97:399-406.
126. Fracchia M, Secreto P, Tabone T, Zaffino C, Pera A, Galatola G.
Serum interferon gamma in primary biliary cirrhosis: effect of ursodeoxycholic acid and prednisone therapy alone and in
127. Louis H, LeMoine O, Peny MO, Gulbis B, Nisol F, Goldman M, Deviere J. Hepatoprotective role of interleukin-10 in galactosamine/lipopolysaccharide induced liver injury.
Gastroenterology 1997;112:935-42.
128. Louis H, LeMoine O, Peny MO, Quertinmont E, Fokan D, Goldman M, Deviere J. Production and role of interleukin-10 in concanavalin-A-induced hepatitis in mice. Hepatology 1997;25:
1382-9.
129. Swain MG, Appleyard C, Wallace J, Wong H, Le T. Endogenous glucocorticoids released during acute toxic liver injury enhance hepatic IL-10 synthesis and release. Am J Physiol 1999;276:
G199-205.
130. Marchant A, Amraoqui Z, Gueydan C, Bruyns C, LeMoine O, Vandenbeele P, et al. Methylprednisolone differentially regulates IL-10 and tumor necrosis factor production during murine endotoxemia. Clin Exp Immunol 1996;106:91-6.
131. Tabardel Y, Duchateau J, Schmartz D, Marecaux G, Shahla M, Barvais L, Leclerc JL, Vincent JL. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men.
Surgery 1996;119:76-80.
132. Vander Poll T, Barber AE, Coyle SM, Lowrey SF. Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia. A clinical research center study. J Clin Endocrinol Metab 1996;81:3604-6.
133. Wang SC, Tsukamoto H, Rippe RA, Schrum L, Ohata M. Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem 1998;105:302-8.
134. Tsukamoto H. Is interleukin-10 antifibrogenic in chronic liver injury?
135. Lee BS, Kim NJ, Jeong HY, Lee HY, Kang DY, Noh SM. Changes in serum cytokine concentration: a morphological study of liver cirrhosis induced by common bile duct ligation in rats. Korean J Intern Med 2003;18:6-12.
136. Nagano T, Yamamoto K, Matsumoto S, Okamoto R, Tagashira M, Ibuki N, Matsumura S, Yabushita K, Okano N, Tsuji T. Cytokine profile in the liver of primary biliary cirrhosis. J Clin Immunol 1999;19:422-7.
137. Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM.
Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol 1996;80:311-20.
個人履歷 中文姓名 : 賴學洲
英文姓名 : Hsueh-chou Lai 出生年月日 : 1962 年 5 月 21 日 中國醫藥學院中醫系(76-82)
E-mail : [email protected] 經歷 :
82−85 中國醫藥學院附設醫院內科部住院醫師
85−87 中國醫藥學院附設醫院內科部住院總醫師及研究員 87−88 中國醫藥學院附設醫院急診部主治醫師
88 迄今中國醫藥學院附設醫院消化系內科主治醫師
88 迄今中國醫藥學院附設醫院消化系內科主治醫師